MA

Mark Asten

Mr Asten has over 30 years of experience in the medical diagnostics and life sciences industry. Much of this time has been in international business development, strategic planning and introduction of new technology. Through Diagnostic Technology, a company he founded, he has been responsible for the development and introduction of technology platforms and technologies into mainstream healthcare use, including HPV DNA testing for cervical cancer screening and the molecular monitoring for both viral infections and cancer treatments. He holds an Adjunct Senior Lectures position at the School of Biotechnology and Biomolecular Science, University of NSW where he has collaborated on research projects related to biosynthetic pathways in bacteria. He is member of risk committee. Former directorships (last 3 years) include Cimtech Limited.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
22/08/2415,329N/A12,500N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
28/04/23
Expiry
120,000$0.015$1,800Options expired
21/04/23
Issued
68,125$0.017$1,158Rights issue
10/11/21
Exercise
75,000$0.050$3,750Exercise of options
10/11/21
Buy
75,000$0.050$3,750Exercise of options
06/08/20
Issued
500,000$0.058$29,000Issue of options